Pamela Ginex, Senior Manager of EBP at The Oncology Nursing Society
The Oncology Nursing Society (ONS) has a long history of using evidence-based practice techniques to facilitate the translation of evidence to practice. For more than 15 years, ONS members have been integral to this process and have worked on our Putting Evidence Into Practice (PEP) teams to identify and synthesize the research evidence on 20 common cancer side effects and symptoms, such as fatigue, dyspnea, depression, pain, and sleep–wake disturbance. The teams are comprised of nurse scientists, advanced practice nurses, and staff nurses. The systematic reviews these teams conducted form the foundation of a practice guideline. In 2018, ONS started the process of transitioning our PEP resources to full symptom management guidelines.
We are happy to announce that five of our PEP topics are being transitioned to cancer symptom management guidelines. The five topics include lymphedema, radiodermatitis, skin effects, constipation, and hot flashes. Each can be significant for patients, and uncertainly remains for clinicians about best practices for management. The PEP teams for each topic have expanded to include interprofessional colleagues with expertise on that topic. The teams have been meeting regularly to identify relevant clinical questions that the guideline should address. Our ultimate goal for these guidelines is for them to guide clinicians to best practices in the care of patients with cancer who are experiencing these side effects. The teams are following national criteria for the development of trustworthy guidelines from the National Academies of Sciences, Engineering, and Medicine, as well as using GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology to ensure the guidelines are rigorous, transparent, and relevant to care today.
Join us at the Clinical Chat ONS Transition to Guidelines on Friday, April 12, to learn more about our transition to guidelines. Together, we can improve symptom management for patients with cancer.